APHL 2021 Member Assembly

APHL

Virtual Event

June 21, 2021 • 3:00 pm ET

2021 APHL Member Assembly

Monday, June 21, 2021
3:00–4:30 pm EDT

Join the Zoom Meeting:
https://aphl.zoom.us/j/95544050350

Join by phone: 646.876.9923
(audio only; no access to Zoom webinar slides/chat)
Webinar ID: 955 4405 0350

AGENDA

Welcome

Call to Order

Service Milestones and In Memoriam

Secretary-Treasurer Report

- Committee Reports page 3
- Approved Member Assembly Minutes 2020 page 27
- Draft Financial Report & Audit page 31
- Incoming Board Members

Open Session

Remarks by Bill Whitmar, former President and Member Emeritus

Remarks by APHL President, Dr. Denise Toney

Adjournment

A conversation with Dr. Rick Bright, Senior Vice President of Pandemic Prevention and Response, Rockefeller Foundation, immediately follows.

APHL ASSOCIATION OF PUBLIC HEALTH LABORATORIES

COMMITTEE REPORT
Quarter: Q1 Jan-Mar 2021
Submission Date: 4/7/2021

Committee: Biosafety and Biosecurity Committee

Accomplishments (up to five):

1) Convened the Biosafety and Biosecurity Committee (BBC) Virtual In-Person Meeting: On March 10-11, 2021, APHL convened the virtual meeting where members were briefed on APHL's coronavirus disease (COVID-19) response and accomplishments, biosafety for non-traditional testing sites, biosafety and biosecurity guidelines, integration of biosafety into quality management systems and effective biosecurity drills and exercises. BBC members identified projects for the upcoming year, which includes guidance for non-traditional testing sites and successful approaches towards integrating biosafety practices with laboratory quality management systems.
2) APHL National Biosafety and Biosecurity Call: APHL held a national call with over 50 public health laboratory biosafety professionals on March 4, 2021. BBC Member, Drew Fayram facilitated the discussion on laboratory biosafety and biosecurity operations during the COVID-19 pandemic and revised biosafety guidelines including the Biosafety in Microbiological and Biomedical Laboratories (BMBL) 6th Edition.
3) COVID-19 Antigen Testing Biosafety Guidance Document: The BBC developed this resource to provide laboratories with recommended biosafety practices to protect personnel and the work area from contamination with SARS-CoV-2 when collecting and testing specimens for COVID-19 using an antigen test.
4) Participated in National and Partner Meetings:
   - BBC members and staff participated in the CDC and Eagleson Institute Steering Committee to develop the program for the 17th CDC International Symposium on Biosafety, scheduled for 2022.
   - BBC Members, Maureen Sullivan and Michael Pentella, and APHL staff participated in the CDC Clinical Laboratory Partners Forum Conference Call on March 29, 2021. The call focused on CDC and partners sharing their activities in response to COVID-19.

Challenges:

COVID-19 response delayed committee projects and overall timelines. Travel restrictions hindered in-person committee meetings

Collaboration (Cross-cutting internal):

Quality Systems and Analytics: During the BBC Virtual In-Person Meeting, the two groups collaborated on discussions involving the integration of biosafety into quality management systems.

Global Health Activities (if applicable):

Position Statement Implementation Activities:

BBC members are reviewing the position statement, Improving Biosafety in Our Nation's Laboratories with the goal to issue an updated document in 2021.

COMMITTEE REPORT
Quarter: Q1 Jan-Mar 2021
Submission Date: 4/9/2021

Committee: Environmental Health Committee

Accomplishments (up to five):

1. Food Chemistry Workgroup was formally created, and convened for the first time during the April EHC call to discuss the Congressional report on metals in baby food. It is composed of members from Environmental Laboratory Sciences, Food Safety, and EHC representing: 4 agriculture laboratories, 2 environmental laboratories, 8 public health laboratories, 3 FDA and 3 USDA liaisons, led by EHC member Michael Wichman (FDA), and staffed by APHL EH and FS staff.
2. One page issue brief developed by the EHC Instrument Service Contract Workgroup was submitted to APHL Communications.
3. The National Biomonitoring Network (NBN) Quarterly Call was held March 26, and a new application for the NBN was received (Texas) and is under consideration by a review panel.
4. Two APHL 2021 annual meeting sessions developed by the EHC were accepted: "We See the Future of High Resolution Mass Spectrometry, and It Looks Bright!" and "Building Laboratory Resiliency for Continuityof Essential Testing During Disasters" (submitted by PHPR).

Challenges:

Collaboration (Cross-cutting internal):

Instrument Service contract work group: Environmental Laboratory Sciences, PHPR, Marketing/Comms

Food chemistry workgroup: Food safety, Environmental Laboratory Sciences

Global Health Activities (if applicable):

N/A

Position Statement Implementation Activities:

New Biomonitoring Position Statement formally adopted by APHL in February.

COMMITTEE REPORT

Quarter: Q1 Jan-Mar

Date of Report:

Committee: Environmental Laboratory Science

Accomplishments (up to five):

1. The committee submitted four session proposals for APHL 2021 and collaborated with EPA on four more. Two committee sessions were accepted, one on wastewater surveillance and another on climate change. The climate session was converted into a plenary.

2. Over 100 people attended the APHL Winter Environmental Laboratory Call. EPA Region 5 Laboratory presented and all section leaders for Standard Methods for Water and Wastewater provided updates and opportunities for laboratories to get involved.

3. The committee reviewed the current status of the developing APHL Ethics Resources webpage and finalized a list on environmental microbiology training opportunities to be made available to all labs.

4. The committee approved the write-up and identified speakers for an APHL session at the May Private Well Class Virtual Conference that will focus on how private well stakeholders can best work with state, local and university laboratories.

5. The committee discussed examples of how environmental laboratories provide essential services during public health emergencies to inform Eric Blank's plenary talk on this topic at the 2021 National Environmental Monitoring Conference in August.

Challenges:

None of note.

Collaboration (Cross-cutting internal):

Environmental Health Committee, Workforce Development Committee - the interdisciplinary radchem workforce shortage workgroup is collaborating via email occasionally as APHL works to determine funding options based upon the finalized proposal.

Environmental Health Committee - Two ELSC members will be participating in the food chemistry workgroup

Global Health Activities (if applicable):

None.

Position Statement Implementation Activities:

The committee's principal state laboratory position statement implementation workgroup met three times and finalized survey questions to determine the current lab status, challenges, and success stories in this area. The committee reviewed the survey and it is near final.

https://www.aphlweb.org/aphl_departments/policy/SitePages/ELSC%20Position%20Statement%20Reports.aspx

COMMITTEE REPORT

Quarter: Q1 Jan-Mar 2021

Submission Date: 4/9/2021

Committee: Food Safety

Accomplishments (up to five):

1) APHL assisted with three PulseNet trainings during the reporting period:
   a. The Alabama laboratory participated in MiSeq training held virtually in 5 sessions between January 12-March 1. One person was trained and has successfully passed WGS laboratory certification.
   b. The Alabama laboratory participated in BioNumerics Analysis training held virtually in 2 sessions in March. Two people were trained and are expected to complete analysis certification soon.
   c. The Houston laboratory participated in BioNumerics Analysis training held virtually in 2 sessions in February. Five people were trained and have successfully passed WGS analysis certification.
2) The FS Committee held another mini virtual meeting February 22 & 23. Topics covered included cross-cutting food and environmental health issues, progress on the NCS Laboratory Framework, current goings on within FDA, an overview of CDC's Food Systems work group, highlights from the 2019 FS survey and a demonstration of the new PulseNet dashboard.
3) The LCF Development Workgroup held a workshop March 8 – 10, 2021 to continue development of the NCS Laboratory Framework. The workgroup incorporated feedback from a validation survey into the Mid-Level General competency statements.
4) FS staff helped beta test and provide feedback on APHL's new training portal that was launched during the reporting period. The training portal is a digital repository for online courses and archived webinars.
5) Several FS members worked with Education and Training staff to develop two additional LCF courses- Waste Management and Basic Laboratory Math. The courses are available on APHL's Training Portal.

Challenges:

No challenges beyond those associated with the pandemic including modified, virtual meetings, limited member time, etc.

Collaboration (Cross-cutting internal):

1. FS staff collaborated with policy staff on a letter addressing FSIS' proposed rule *Changes to Accreditation of Non Federal Analytical Testing Laboratories.* Input was sought from the committee and HAF Subcommittee.
2. FS staff also worked with Lorelei Kurimski and QSA staff on a food testing module for APHL's PHL Systems Database (PHLSD).
3. FS staff identified members and have been participating on a newly formed FS Chemistry work group formed by EH.
4. FS staff continued to work with Cathy Johnson and her staff on several FDA CoAg activities including the LCF work.
5. FS staff collaborated with ID and Informatics on an updated ELC guidance tool to assist members

with ELC grant applications.

Global Health Activities (if applicable):

Position Statement Implementation Activities:

https://www.aphlweb.org/aphl_departments/policy/SitePages/EH%20Position%20Statement%20Reports.aspx

COMMITTEE REPORT
Quarter: Q1 Jan-Mar 2021
Submission Date: 4/8/2021

Committee: Global Health Committee

Accomplishments (up to five):

1. The Global Health Committee held monthly calls in the months of January and February. Our March monthly call was adjourned to April in order to strategize with the chair on steps forward for the working groups and the needs of the committee.
2. The Business Plan Work Group completed the draft of the Global Health Strategy and shared the draft with APHL leadership for review and commenting. The working group will present the strategy to the Board of Directors on the May 2021 BOD call.
3. The Global Health Committee in collaboration with staff members submitted 5 sessions for the 2021 Virtual Annual Conference and one plenary session was accepted for the conference on: Laboratory Systems: The Global Response to the COVID 19 Pandemic

Challenges:

Our ability to move work group projects forward continues to be dependent on the laboratory member's time commitments in response to COVID-19. As of now, our members are stretched with their laboratory and work commitments and have not been able to devote as much time as needed to the committee work plan and activities

Collaboration (Cross-cutting internal):

None to report this quarter

Global Health Activities (if applicable):

N/A

Position Statement Implementation Activities:

https://www.aphlweb.org/aphl_departments/policy/SitePages/EH%20Position%20Statement%20Reports.aspx

APHL ASSOCIATION OF PUBLIC HEALTH LABORATORIES

COMMITTEE REPORT
Quarter: Q1 Jan-Mar 2021
Submission Date: 4/9/2021

Committee: Informatics

Accomplishments (up to five):

1. The informatics committee held a two day virtual meeting (in lieu of annual in-person) on March 8 -9, 2021. Committee members engaged with our Policy Program, leadership staff, and CDC on the Data Modernization Initiative and advancing Electronic Test Orders and Results as the biggest priorities and topics for the next several years.

2. Between 2/9 and 3/26, Informatics fielded a survey around ETOR capabilities in public health labs. This survey, designed by the ETOR Taskforce and several committee members, asked laboratories to evaluate their infrastructure, workforce, and policies regarding electronic data exchange, to determine where gaps and opportunities exist. This landscape analysis will be used as the foundation to develop and target specific technical solutions for laboratories to achieve ETOR as part of the Digital Modernization Intitiative.

3. The Informatics committee monthly meetings now feature a "Committee Spotlight" as a standing agenda item. This 10 – 15 minute segment includes a presentation from the Inforamtics Program, CDC, technical contractors, or committee members themselves on a topic of relevance and interest to the committee at large to promote a sense of cohesion and open up opportunities for collaboration.

4. The March release of the Informatics Newsletter featured a "member spotlight" on committee member extraordinaire, Ivan Dudik, IT Liaison in TX.

5. In February and March, several committee members served as beta-testers for the "Introduction to LIMS" course, currently in CDC Clearance and estimated for release later in April.

Challenges:

In February, 2021, the Informatics Committee Chair announced she was leaving the Missouri PHL and moving to the OpenELIS Foundation, and as such, resigning from her position on the committee. We are currently approaching members to get a chair in place for the coming year as we believe the Informatics committee has an important and strategic role to play with the disbursement of DMI funding and a definitive need to achieve widespread and centralized technical solutions.

Collaboration (Cross-cutting internal):

NBS and Informatics members and staff continue to attend one another's committee/subcommittee meetings

Global Health Activities (if applicable):

Began discussions with Reshma Kakkar on the possibility of a Global Health/Informatics retreat in the months ahead to level set on informatics global work and opportunities. Additionally, the introductory courses to laboratory informatics "Life of a Specimen" and "Life of a Result", developed in part by the

Informatics Workforce subcommittee are currently being reviewed for potential translation into Thai, French, and several other languages.

Position Statement Implementation Activities:

Committee: Knowledge Management Committee

Accomplishments (up to five):

1. KMC has continued to meet monthly with great attendance and participation and all workgroups have met on a monthly basis to work on their respective projects.
2. **Next Generation Recruitment & Retention Resource**: the workgroup finalized the recruitment and retention guidance document that they began designing pre-COVID and are continuing the promotion of the document.
3. **Next Generation Recruitment & Retention:** the workgroup identified 5 topic areas from the 2020 next generation focus group that they wanted to focus on in a PHL generational survey. The topics include: knowledge retention & transfer, team building, communications across generations, workplace culture, and diversity, equity, & inclusion (DEI). With help from the WDC, APHL's DEI workgroup and the APHL Board DEI workgroup, the survey questions were finalized and the survey is set to launch in April 2021.
4. **Member Resource Center (MRC):** the workgroup contacted all of the authors of the workforce training documents and began the great task of categorizing each document into the different topic areas in the MRC.
5. **Knowledge Retention Toolkit (KRT)**: the workgroup, KM committee and TB subcommittee have reviewed the final suggestions/improvements for the TB tab in the toolkit and plan to finish the tab and work on the promotional campaign in April 2021. The workgroup (minus the TB subcommittee) will use the remainder of the committee year to work on improving the older tabs in the toolkit, starting with the Lab Manager tab.

Challenges:

One major challenge has been trying to find the balance between carrying on committee work for the year and respecting our committee member's limited time as everyone has been knee-deep in COVID work in their PHLs.

Collaboration (Cross-cutting internal):

-KMC & LSS – PHLSD, MRC & ESI
-KMC & EHC/ELSC – PHLSD
-KMC & TB subcommittee – Knowledge Retention Toolkit
-KMC & Workforce Development Committee – Next Generation Recruitment & Retention Resource

Global Health Activities (if applicable):

None.

COMMITTEE REPORT
Quarter: Q1 January-March 2021
Submission Date: April 9, 2021

Committee: Laboratory Systems and Standards

Accomplishments (up to five):

1. **Committee calls:** The LSS committee continued to hold monthly conference calls in January, February and March. Recent topics included the session proposals for the 2021 APHL Annual Conference and a discussion of strategies that PHL are implementing to address the issues of resource and staffing shortages from a QI perspective.
2. **Quality Improvement Forum (QIF) Call:** One QIF call was held this quarter, and it was titled "CLIA Regulatory Considerations During COVID." Kristin Schieble, the laboratory operations manager at the City of Milwaukee Health Department Laboratory, and Jeff Groff, the Laboratory Certification and CLIA Program Manager for the Colorado Department of Public Health and Environment, discussed CLIA topics in both laboratory and non-traditional COVID testing sites. Helpful guidance, resources and lessons learned were shared. Planning for an APHL QIF call titled "Surviving Regulatory Inspections" is underway.
3. **Economic and Social Impact workgroup:** As of February 2021, the PHL Impact tool, user manual, and draft template report have been CDC cleared. The tool is currently being modified for 508 compliance before posting it and other material on the CDC Health Economics and Modeling Unit (HEMU) webpage.
4. **PHLSD:** Susanne Zanto, the PHLSD consultant, continued to reach out to laboratories for environmental test data to populate the PHLSD and is working to update the COVID testing and equipment. The beta testing of the Human Food and Animal Feed list went well. APHL recently met with the contractor to get the other three remaining lists built for the PHLSD – animal and insects, forensic/toxicology, and the food list.
5. **Other workgroups:** The CLIA workgroup met in January, February and March to review the CLIA checklist and modify it as necessary. The L-SIP tool update workgroup met in January, February and March to discuss how to best incorporate diversity, equity and inclusion concepts into the tool.

Challenges:

LSS committee members have been very busy with the COVID-19 response, and therefore are not able to devote the usual time to committee activites. However, they continue to meet as their schedules allow.

Collaboration (Cross-cutting internal):

The workgroups composed of LSS and Knowledge Management committee members continue to work on the Economic and Social Impact (formerly Return on Investment) and the Public Health Laboratory Systems Database projects.

Global Health Activities (if applicable):

n/a

Position Statement Implementation Activities:

https://www.aphlweb.org/aphl_departments/policy/_layouts/15/start.aspx#/SitePages/Laboratory%20Systems%20and%20Standards%20Position%20Statement%20Reports.aspx

https://www.aphlweb.org/aphl_departments/policy/PositionStatements/How%20to%20enter%20committee%20activity%20into%20progress%20report%20tables.pdf

APHL ASSOCIATION OF PUBLIC HEALTH LABORATORIES

COMMITTEE REPORT

Quarter: Q1 Jan-Mar 2021

Submission Date: 4/9/2021

Committee: Newborn Screening Committee

Accomplishments (up to five):

1) The Newborn Screening Committee held an extended conference call on February 9, 2021 to replace an in-person meeting that normally would have been held at this time. The committee discussed how NBS programs count conditions and the need to harmonize condition counting, results harmonization, workforce issues brought about by COVID-19, and APHL's efforts to meet pipette tip needs and other supply shortages.
2) As a result of the condition counting discussion, the committee decided to assemble a task force to develop a proposal on how to harmonize how conditions are counted across NBS programs.
3) The NewSTEPs Short Term Follow-up Work Group began the first round of virtual meetings for the new Follow-up Learning Exchange (FLEX) Program. The first 8 NBS follow-up program coordinators were paired with mentors to help address their unique challenges and collaborate with other states on solutions.
4) The Epidemiology User Group held a call on February 16, 2021. Ankit Sutaria, an epidemiologist with the Georgia NBS program presented on NBS bloodspot and critical congenital heart disease (CCHD) incidence, trends, characteristics, etc. to help programs learn about epidemiological methods in analyzing data related to metabolic, hemoglobin, hormonal, and CCHD.
5) The NewSTEPs New Disorders Workgroup hosted a webinar series focused on screening for disorders that are outside of the current Recommended Uniform Screening Panel (RUSP). This three-part webinar series provided updates from programs screening for disorders not currently on the RUSP, both as pilot programs and as components of universal screening. Over 400 individuals participated in the series.

Challenges:

N/A

Collaboration (Cross-cutting internal):

The NBS Workforce Taskforce and APHL's Workforce Development Committee met to discuss cross-cutting activities and potential future collaborations. The NBS Workforce Taskforce and Workforce Development Committee also discussed and co-developed an abstract for the APHL2021 on the use of laboratory-wide cross-training initiatives to build more sustainable laboratory infrastructure.

Global Health Activities (if applicable):

N/A

Position Statement Implementation Activities:

https://www.aphlweb.org/aphl_departments/policy/SitePages/EH%20Position%20Statement%20Reports.aspx

NBS Contingency Planning: APHL NBSG program is drafting a one (or two-) pager to address continuity of operations planning (COOP) during a global pandemic. Part of the focus will be on implementing telehealth, but will also include other considerations. (implementation step 2)

Parental Consent for Newborn Screening: In collaboration with APHL Public Policy program, discussed recently proposed state legislation affecting NBS, genetic privacy, and/or parental consent with the NBS committee and Legal and Legislative workgroup. (implementation step 2)

APHL ASSOCIATION OF PUBLIC HEALTH LABORATORIES

COMMITTEE REPORT
Quarter: Q1 Jan-Mar 2021
Submission Date: 4/9/2021

Committee: Public Health Preparedness and Response (PHPR)

Accomplishments (up to five):

1. Engaged with the American Society for Microbiology (ASM) on Protocol Updates: Members from the Sentinel Laboratory Partnerships and Outreach Subcommittee (SLPOS) worked with ASM representatives to update the Laboratory Response Network (LRN) Sentinel Level Clinical Laboratory Protocol for Anthrax.

2. Convened the Public Health Preparedness and Response (PHPR) Committee Virtual Meeting: On January 27 and February 3, 2021, APHL convened the PHPR Committee virtual meeting where members met to discuss topics impacting public health preparedness and response, including the role of sequencing and other technologies in detecting emerging threats, current Centers for Disease Control and Prevention (CDC) priorities to engage with clinical laboratories to support testing during a public health response, updates from and opportunities to collaborate with the Environmental Health program, the future of the Laboratory Response Network, and recent public health laboratory engagement with first responders to support response to COVID-19.

3. Addressed Changes to the Definition of Sentinel Clinical Laboratories: Members from PHPR and SLPOS met with CDC/ Division of Laboratory Systems to discuss feedback from the LRN Joint Leadership Committee (JLC) regarding proposed changes to the definition of sentinel clinical laboratories. This is an ongoing priority to address public-private laboratory partnerships.

4. Provided feedback to CDC, Division of Preparedness and Emerging Infections (DPEI), Laboratory Preparedness and Response Branch (LPRB): In March 2021, the LRN Operational Workgroup convened a virtual meeting to discuss the Laboratory Data Portal Result Messenger (LDPRM), outline priority topics for future LRN quarterly conference calls, and update the LRN Operational Workgroup purpose statement. The feedback provided will improve communication and information sharing within the LRN for Biological Threats Preparedness (LRN-B).

Challenges:

COVID-19 response efforts delayed Committee projects.

Collaboration (Cross-cutting internal):

Environmental Health Committee: The PHPR Committee and APHL PHPR staff submitted a plenary session abstract to the APHL Annual Conference on laboratory

resiliency planning. The session was accepted in March.

Global Health Activities (if applicable):

None

Position Statement Implementation Activities:

None

APHL ASSOCIATION OF PUBLIC HEALTH LABORATORIES

COMMITTEE REPORT
Quarter 1: Jan-Mar 2021

Committee: Workforce Development Committee

Accomplishments (up to five):

1. The Workforce Development Committee submitted 3 session proposals for APHL 2021, and collaborated with the NBS Workforce Taskforce on another proposal. The annual conference committee accepted one proposal for the conference.
2. Committee members continue to make plans to offer another session of the board certification boot camp in 2021. The tools for online sharing are currently available and being used by interested individuals.
3. Nominations were solicited for the 2021 Thomas E. Maxson Education, Training & Workforce Development Award. Seven (7) nominations were received. Recipient will be announced at virtual PHLTC in early June.
4. Members of the committee continue to work with other APHL committees, including: the Environmental Laboratory Science Committee (ELSC) as part of the radiochemistry workforce shortage workgroup to develop a detailed training program proposal and an executive summary of the proposal; the Knowledge Management Committee (KMC) on Diversity, Equity and Inclusion (DEI) topics, particularly updating the L-SIP tool to include DEI concepts.
5. Members of the committee assisted the ELAN (Emerging Leader Alumni Network) with its March 2021 quarterly call on "Best Practices".

Challenges:

Prioritization of projects over the next few months. Availability of members for participation in ongoing and upcoming projects.

Collaboration (Cross-cutting internal):

1. Collaboration continues with the Knowledge Management Committee (KMC) on resources for members related to recruitment and retention.
2. Collaboration began with APHL's Global Health Team following its interest in using materials from the DrPH program for various global health projects.
3. Collaboration continues with the Environmental Laboratory Science Committee (ELSC) on the radiochemistry workforce shortage workgroup.
4. Collaboration continues with a subgroup of the Knowledge Management Committee (KMC) on Diversity, Equity and Inclusion (DEI) topics.

Global Health Activities (if applicable):

Position Statement Implementation Activities:

APHL ASSOCIATION OF PUBLIC HEALTH LABORATORIES

COMMITTEE REPORT

Quarter: Q1 Jan-Mar

Date of Report:

Committee: Infectious Disease

Accomplishments (up to five):

1. The committee submitted four session proposals for APHL 2021 and collaborated with EPA on four more. Two committee sessions were accepted, one on wastewater surveillance and another on climate change. The climate session was converted into a plenary.

2. Over 100 people attended the APHL Winter Environmental Laboratory Call. EPA Region 5 Laboratory presented and all section leaders for Standard Methods for Water and Wastewater provided updates and opportunities for laboratories to get involved.

3. The committee reviewed the current status of the developing APHL Ethics Resources webpage and finalized a list on environmental microbiology training opportunities to be made available to all labs.

4. The committee approved the write-up and identified speakers for an APHL session at the May Private Well Class Virtual Conference that will focus on how private well stakeholders can best work with state, local and university laboratories.

5. The committee discussed examples of how environmental laboratories provide essential services during public health emergencies to inform Eric Blank's plenary talk on this topic at the 2021 National Environmental Monitoring Conference in August.

Challenges:

None of note.

Collaboration (Cross-cutting internal):

Environmental Health Committee, Workforce Development Committee - the interdisciplinary radchem workforce shortage workgroup is collaborating via email occasionally as APHL works to determine funding options based upon the finalized proposal.

Environmental Health Committee - Two ELSC members will be participating in the food chemistry workgroup

Global Health Activities (if applicable):

None.

Position Statement Implementation Activities:

The committee's principal state laboratory position statement implementation workgroup met three times and finalized survey questions to determine the current lab status, challenges, and success stories in this area. The committee reviewed the survey and it is near final.

https://www.aphlweb.org/aphl_departments/policy/_layouts/15/start.aspx#/SitePages/ID%20Position%20Statement%20Reports.aspx

https://www.aphlweb.org/aphl_departments/policy/SitePages/ELSC%20Position%20Statement%20Reports.aspx

Committee: Board of Directors

Accomplishments (up to five):

APHL Board members synthesized the results of an environmental scan with select members, partners and staff during meetings with Laurie Schulte of The Clarion Group. Subsequent virtual sessions were conducted to draft the central challenge and strategic priorities. In a final meeting, a draft APHL Strategic Map for the next two years was drafted.

The Board authorized APHL to enter into the proposed $2,000,000 Commercial Note with Truist Bank. This would establish a new line to establish a new line of credit with Truist Bank, parent company of the association's existing commercial bank, SunTrust Bank. The proposed Commercial Notes with Truist Bank would enable APHL to borrow funds on an as needed basis at a lower interest rate than currently charged under APHL's existing $1,500,000 line of credit with Morgan Stanley Bank, N.A.

The Board approved the charge for the Task Force to Engage Environmental and Agricultural Laboratories. This Task Force, created at the direction of Bill Whitmar, APHL President, to engage and demonstrate the importance of Associate Institutional Member Laboratories (Agricultural, Environmental, Food, Chemical). APHL recognizes that state, local and tribal agricultural (food/chemical) and environmental health laboratories protect public health in their area of service. These associate institutional members are key stakeholders in our vision for a healthier world through quality laboratory systems. The **Task Force** shall provide strategies to APHL and the Board on how to better engage and serve these partners, including understanding how to attract and maintain agricultural and environmental health laboratory members.

The board approved the nomination of Grace Kubin to fill the term of Past-President, effective July 1, 2021 to June 30, 2022 due to the impending retirement of Bill Whitmar, which would have left that seat vacant.

Board accepted Financial Statements submitted by the Finance Committee

Challenges:

CEO reported to BOD on challenges of member engagement in position statement review, input and approval.
Board was asked to provide input and perspectives on the challenges laboratories are facing in procurement.

Collaboration (Cross-cutting internal):

Collaborations with senior staff on strategic map

Global Health Activities (if applicable):

N/A

Position Statement Implementation Activities:

Board amended the position statement, Improving Biosafety in our Nation's Laboratories, extending the sunset date to December 2021 allowing the Biosafety and Biosecurity Committee additional time for revisions.

Committee: Diversity, Equity and Inclusion Task Force

Accomplishments (up to five):

1. The Task Force identified a vendor that can provide a two-hour, introductory level diversity, equity, and inclusion (DEI) training to not only the Task Force but also the entire APHL community. The training will provide an overview of DEI terminology, propose suggested language to discuss and describe DEI experiences, and consider current events and topics in DEI. The training also includes an additional one-hour post presentation wrap-up and a reading list.
2. The Task Force contributed to the June 2021 Lab Matters article discussing DEI in a public health laboratory.
3. Task Force members attended a virtual cultural awareness and inclusion seminar with Devin C. Hughes.
4. Multiple Task Force members enrolled in a free DEI in the work place certificate through the University of South Florida.
5. The Task Force continues to create an inclusive space where ideas, thoughts, opinions, knowledge and experiences can be shared freely and without judgement.

Challenges:

1. The Task Force continued to compose a diversity survey for distribution to member laboratories. The diversity survey nears completion but is not finalized. Its completion requires additional sub-group meetings to complete and task force member scheduling challenges exist due to the COVID-19 pandemic.

Collaboration (Cross-cutting internal):

1. Assisted Emerging Leaders Program Cohort 13 with a DEI infographic. Contributions of the task force members included review and editing of the infographic content and resource suggestions.
2. Collaborated with APHL diversity, equity and inclusion staff on ideas for the 2021 APHL Virtual Conference
3. The Environmental Health Manager and Specialist attended a Task Force meeting to begin discussing opportunities to collaborate on environmental justice topics and also for members to share environmental justice activities occurring within their respective laboratories. A number of innovative initiatives were shared, including, but not limited to the following: creation of a state-level environmental justice office, an environmental justice journal club, and interpreting biomonitoring data as a way to evaluate environmental justice.

Global Health Activities (if applicable):

Position Statement Implementation Activities:

APHL ASSOCIATION OF PUBLIC HEALTH LABORATORIES

COMMITTEE REPORT

Quarter: Q1 Jan-Mar 2021

Submission Date: 4/9/2021

Committee: Opioids Biosurveillance Task Force (OBTF)

Accomplishments (up to five):

1) The OBTF met on January 26, 2021 and reached consensus on moving forward with a Neonatal Abstinence Syndrome (NAS)-related document for public health scientists, epidemiologists, and public health partners. This document will consider available surveillance sources and the existing data gaps (i.e., laboratory identification of drugs).
2) An outline of this document was provided to the OBTF in March 2021 for review and discussion on their April 5, 2021 call. During Q2, the OBTF will divide into workgroups (Epidemiology, Laboratory Testing, Ethical/Social/Legal Considerations) and work on specific sections of the document.
3) In February 2021, the OBTF Chair was invited to present on the work of the OBTF and opioids biosurveillance at a plenary session for the upcoming European Society of Medicine General Assembly, August 2021, Berlin, Germany.
4) In March 2021, a session proposal submitted on behalf of the OBTF was accepted as a plenary session for the APHL 2021 annual conference. The OBTF Chair, an OBTF member, and an active APHL Opioid Community of Practice (CoP) member will present at this session.

Challenges:

Competing priorities of high-level public health officials on the OBTF who have and continue to serve active roles in the COVID-19 response at both state and federal levels.

Collaboration (Cross-cutting internal):

Continued work with the APHL Newborn Screening Committee liaison who serves on the OBTF.

Global Health Activities (if applicable):

None at this time.

Position Statement Implementation Activities:

None at this time.

COMMITTEE REPORT
Quarter: Q1 Jan-Mar 2021
Submission Date:

Committee: Task Force to Engage Environmental and Agricultural Members

Accomplishments (up to five):

Task Force has divided areas of focus for three workgroups

Outreach – how to attract potential members

Benefits – to review benefits offered and identify gaps and ways to highlight benefits that may not get the attention deserved. Members discovered through discussion that not everyone is aware or has taken advantage of significant benefits being offered by APHL.

Comparison – a review has been done on what comperable organizations offer; how we differ and how the products and services provided by APHL could be of greater value. This information will be of significant valule in outreach efforts.

All groups are making progress on these assignments

Task force expects to finalize and execute the survey of existing and potential PHAI members in the 2^{nd} Quarter

Challenges:

Task Force members are challenged to identify with Public Health Associate Institutional denomination. There is a discussion whether PHAI defines well who they are and their functions as Public Health laboratories.

Collaboration (Cross-cutting internal):

Task Force has worked with Membership as a resource for information and expects to collaborate further as it continues to address objectives.

Global Health Activities (if applicable):

N/A

Position Statement Implementation Activities:

N/A

APHL Member Assembly

June 17, 2020

Conducted via Webinar in conjunction with the

Weekly all members COVID call

Call to Order	The meeting was called to order at 3:05 pm, EDT. President Kubin welcomed all attending the 2020 Member Assembly. A quorum was present to conduct all business before the assembly.
Recognition of New and Acting Laboratory Directors for 2020	<u>New Laboratory Directors</u> **Myra Kunas, Interim** Minnesota Public Health Laboratory **Kristina Hsieh** Alameda County Public Health Laboratory **Helen Reid, Acting** Vermont Public Health Laboratory **Mohamad Alsabban** Guam Department of Public Health & Social Services **Bernadette Matthis** Philadelphia Public Health Laboratories **Holly Hansen** Southern Nevada Public Health Laboratory **Lori Pillsbury** Oregon Department of Environmental Quality **Atwell Coleman** South Carolina Public Health Laboratory **Mark Pandori** Nevada State Public Health Lab UNV-R **Megan Crumpler, Acting** Long Beach Public Health Laboratory **Scott Shone** North Carolina State Laboratory of Public Health **Kristina McCallum, Acting** Colorado Department of Agriculture **Michael Edwards** New Mexico Public Health Laboratory **Harmeet Kaur** San Joaquin County Public Health **Richard Tulley, Interim** Louisiana Public Health Laboratory

Rachel Rees
New Member Lab
Sonoma County Public Health Laboratory

Retirements

Retirements

Joanne Bartkus
Minnesota Public Health Laboratory

Mary Celotti
Vermont Public Health Laboratory

Patricia Ann Dadone
Santa Clara County Public Health Laboratory

Keith Wegner
Colorado Department of Agriculture

In Memoriam

Dr. Pedro J. Santiago-Borrero
FEBRUARY 25, 1935 – JULY 12, 2019
Founder
Puerto Rico Newborn Screening Program

Dr. Alexander Ramon
September 30, 2019
Assistant Commissioner (retired)
Director of the Laboratories in the Sexual Health Clinics (former)
New York City Department of Health and Mental Hygiene

John M. "Jack" DeBoy II
June 14, 1946 – October 8, 2019
Former Div. Chief, Asst. Dir., Deputy Dir, and Director of the Laboratories Administration
Maryland Dept. of Health and Mental Hygiene

James A. Gibson
November 3, 2019
Assistant Director, Retired
Tennessee Department of Health Laboratory Services

Secretary-Treasurer's Report	The report was presented by Dr. Daphne Ware, Secretary-Treasurer, who began the report by reviewing the contents of the Member Assembly Book. • Programmatic Committee Reports (1st Quarter 2020) • Approved 2019 Member Assembly Minutes • Unaudited Financial Statements for 2019 • Corporate Support for 201 Dr. Ware advised the assembly that the financial statements are presented in draft form because board had not yet accepted the report at the time the book was published. APHL's assets as of Dec 31, 2019 were \$10.6m compared to \$9.4m in the prior year. Assets Increased by \$1.2m (12%). Liabilities were \$7.5m in fiscal year 2019 compared to \$7.2m in prior year. Liabilities slightly increased by \$0.3m (4%). Net Assets were \$3.2m as of Dec 31, 2019 versus \$2.2m in prior year. Net assets increased by \$0.97m (45%) For the year ended December 31, 2019 APHL showed "Support and Revenue" for \$60.3m compared to \$51.5m in FY18. The revenue increased by \$8.8m (17%). 95% of "Support and revenue" was earned from Grants & Cooperative agreements Expenses reported were \$59.3m in FY19 vs. \$52.2m in FY18. Expenses increased by \$7.1m (14%). 89% of expenses were incurred for the "Program services" & 11% for the "Management & General" support. The organization reported net assets increase of \$0.97m-(profit) in FY19 compare to the reduction in net assets of \$0.64m (loss) in FY18 which \$1.27m higher than budgeted deficit of \$0.30m.
Board of Directors Election	APHL Board Election Denise Toney, Ph.D. (HCLD), (President-Elect) Laboratory Director Virginia Division of Consolidated Laboratory Services Timothy Southern PhD, D(ABMM) (PHI-State) Public Health Laboratory Director South Dakota Department of Health Sanjib Bhattacharyya, PhD (PHI-Local) Special Deputy Health Commissioner City of Milwaukee Health Department Sally Flowers, PhD (PHAI) Laboratory Administrator Nebraska Department of Agriculture

Address by President Grace Kubin	President Kubin reflected on the past year. Her priorities at the start of her term were workforce development and biosafety and these priorities became interwoven with the COVID response. Dr. Kubin remarked that the public health laboratory workforce has shown great drive and resourcefulness in navigating the changing landscape in order to get testing done, such as during the EVALI response last summer. For the COVID pandemic currently occurring, the ability of laboratorians to adjust to constantly changing guidelines when trying to maintain a safe working environment showed their ingenuity and drive when it matters most. She also expressed thanks to all of the APHL members and staff for providing collaboration and assistance during the past year.
Address by President-Elect Bill Whitmar	President-elect Bill Whitmar outlined his priorities for his upcoming term. Ongoing priorities include COVID, by default, sustained Public Health surveillance and funding, solidifying partnerships and strengthening leadership. He also highlighted his plans to: 1. leveraging public health labs' new stature and unique capability for connection to lay the foundation for an enhanced national laboratory system. 2. launch a task force that will develop strategies to (1) bring together affiliate and public health labs that share a jurisdiction; and (2) better integrate affiliate members into APHL's work at both the state and national levels. 3. establish a task force on health equity that can help us look inward, and see what we can do in our laboratories, and in our association. He concluded his address by reminding members of the importance of self-care and urged them to take time to address these needs.
Adjournment	The meeting was adjourned at 3:29 pm EDT

Date: June 21, 2021
To: APHL Members
From: Daphne Ware, PhD, APHL Secretary-Treasurer

Re: Secretary-Treasurer's financial report

Enclosed is a draft copy of APHL's financial statements for the fiscal year ended December 31, 2020. There are several items that I would like to highlight for you.

Every year APHL receives a financial audit and a compliance audit. The purpose of the financial audit is to provide independent assurance that management has presented fairly the APHL's financial performance and position. The second is an audit for compliance with the provisions of 2 CFR 200 (also known as the Uniform Guidance). This audit is required for any entity receiving over $750,000 per year in federal funding. In this audit, the auditors review our internal controls over the federal funds as well as our compliance with the requirements for the federal funds received.

While the audit was not finalized in time for inclusion in the Member Assembly report, we are expecting that the auditors' opinion will be an unqualified or "clean" opinion. This is consistent with prior year audits.

As of December 31, 2020, the Association had assets of $15,711,154 and liabilities totaling $10,068,746, with net assets of $5,642,408. The organization reported an increase to net assets (profit) of $2,488,966. The actual profit is $ 2,320,781.00 greater than the budgeted profit of $168,185. The higher than budgeted operational profit is mostly due to the following factors:

- New revenue contracts (AIMS+ and other COVID related contracts)
- Higher than budgeted indirect cost recovery
- Return on investment portfolio

As part of the Uniform Guidance audit, the auditors issue a report on internal control over financial reporting and a report on compliance with Uniform Guidance requirements. According to the draft audit report received, there are not any significant deficiencies or material weaknesses in either report.

In addition to the organization's financial performance. The Secretary-Treasurer is required to report on the amount of corporate support for the latest audited fiscal year, which includes support from January 1, 2020 through December 31, 2020. For FY2020, the total amount of corporate support was $698, 280 provided by 62 companies. The Corporate Support Report shows which commercial organizations provided corporate support by the category of support provided. Those categories include corporate (sustaining) membership dues, APHL conferences and meetings support, and miscellaneous revenue.

APHL Financial Report Summary as of December 31, 2020

<u>Financial Statement (draft audited statements)</u>

- ***<u>Statement of Financial Position</u>***

    - *Assets:* APHL's assets as of Dec 31, 2020 are $15.7m compared to $10.6m in prior year. Assets mostly consist of Grants & Prepaids (53%), Investments (30%) and Cash (11%). During the fiscal year assets increased by $5.1m (48%).

    - *Liabilities and Net assets:*
      APHL's liabilities as of Dec 31, 2020 are $10.1m and $7.4m in prior year. Liabilities have increased by $2.7m (35%). Liabilities mostly consist of Accrued expenses (34%), Deferred revenue (23%) and Accounts Payable (38%).
      Net assets have increased by $2.4m (75%) and are $5.6m in FY20 vs. $3.2m in FY19.

- ***<u>Statement of Activities:</u>***

    - Changes in net assets: Total net profit for the year ending December 31, 2020 was around $2.5m.

    - Revenue: FY20 Revenue was $64.2m vs. $60.2m in FY19. Revenue increased by $4m (7%). 88% of revenue was received from Grants & cooperative agreements and the rest from AIMS+, revenue contracts and membership activities

    - Expenses: FY20 expenses were $61.8m vs. $59.3m in FY19. Expenses increased by $2.5m (4%). 87% of expenses were incurred for "Program services" & 13% for "Management & General".

ASSOCIATION OF PUBLIC HEALTH LABORATORIES, INC. AND AFFILIATES

FINANCIAL AND FEDERAL AWARD COMPLIANCE EXAMINATION

FOR THE YEAR ENDED DECEMBER 31, 2020

ASSOCIATION OF PUBLIC HEALTH LABORATORIES, INC. AND AFFILIATES

CONTENTS

AUDIT REPORT ON CONSOLIDATED FINANCIAL STATEMENTS

ASSOCIATION OF PUBLIC HEALTH LABORATORIES, INC. AND AFFILIATES

FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019

ASSOCIATION OF PUBLIC HEALTH LABORATORIES, INC. AND AFFILIATES

CONTENTS

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors
Association of Public Health Laboratories, Inc. and Affiliates
Silver Spring, Maryland

Report on the Financial Statements

We have audited the accompanying consolidated financial statements of the Association of Public Health Laboratories, Inc. and Affiliates (collectively, the Association), which comprise the consolidated statements of financial position as of December 31, 2020 and 2019, and the related consolidated statements of activities and changes in net assets, functional expenses and cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Association as of December 31, 2020 and 2019, and the consolidated changes in its net assets, functional expenses and cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Other Matter

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The Schedule of Expenditures of Federal Awards on pages I-(22 - 25), as required by *Title 2 U.S. Code of Federal Regulations (CFR) Part 200*, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance),* is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated on our consideration of the Association's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of this report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Association's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Association's internal control over financial reporting and compliance.

ASSOCIATION OF PUBLIC HEALTH LABORATORIES, INC. AND AFFILIATES

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
AS OF DECEMBER 31, 2020 AND 2019

ASSETS

	2020	2019
Cash and cash equivalents	$ 1,794,028	$ 13,288
Investments	4,801,168	4,273,580
Accounts receivable, net of allowance for doubtful accounts of $7,081 and $20,224 in 2020 and 2019, respectively	75,206	398,832
Grants and contracts receivable	6,451,042	4,551,369
Prepaid expenses and other assets	1,822,175	296,459
Furniture, equipment, leasehold improvements and website redesign, net of accumulated depreciation and amortization of $2,185,237 and $1,922,123 for 2020 and 2019, respectively	767,535	1,030,649
TOTAL ASSETS	**$ 15,711,154**	**$ 10,564,177**

LIABILITIES AND NET ASSETS

	2020	2019
LIABILITIES		
Accounts payable	$ 3,839,197	$ 1,908,328
Accrued expenses	3,419,337	3,899,720
Deferred revenue and refundable advances	2,306,390	979,496
Deferred rent and improvement allowance	503,822	623,191
Total liabilities	10,068,746	7,410,735
NET ASSETS		
Without donor restrictions	5,602,408	3,153,442
With donor restrictions	40,000	-
Total net assets	5,642,408	3,153,442
TOTAL LIABILITIES AND NET ASSETS	**$ 15,711,154**	**$ 10,564,177**

See accompanying notes to consolidated financial statements.

ASSOCIATION OF PUBLIC HEALTH LABORATORIES, INC. AND AFFILIATES

CONSOLIDATED STATEMENTS OF ACTIVITIES AND CHANGES IN NET ASSETS FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019

	2020		
	Without Donor Restrictions	With Donor Restrictions	Total
SUPPORT AND REVENUE			
Contributions	$ 50,000	$ 240,000	$ 290,000
Grants and contracts	61,776,063	-	61,776,063
Conferences and exhibits	374,188	-	374,188
Membership dues	1,088,173	-	1,088,173
Investment income, net	528,063	-	528,063
Publications and other	193,627	-	193,627
Net assets released from donor restrictions	200,000	(200,000)	-
Total support and revenue	64,210,114	40,000	64,250,114
EXPENSES			
Program Services	53,702,166	-	53,702,166
Supporting Services:			
Management and General	8,058,982	-	8,058,982
Total expenses	61,761,148	-	61,761,148
Changes in net assets	2,448,966	40,000	2,488,966
Net assets at beginning of year	3,153,442	-	3,153,442
NET ASSETS AT END OF YEAR	**$ 5,602,408**	**$ 40,000**	**$ 5,642,408**

See accompanying notes to consolidated financial statements.

ASSOCIATION OF PUBLIC HEALTH LABORATORIES, INC. AND AFFILIATES

CONSOLIDATED STATEMENTS OF ACTIVITIES AND CHANGES IN NET ASSETS
FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019

	2019		
	Without Donor Restrictions	With Donor Restrictions	Total
SUPPORT AND REVENUE			
Grants and contracts	$ 57,560,417	$ -	$ 57,560,417
Conferences and exhibits	1,139,045	-	1,139,045
Membership dues	678,694	-	678,694
Investment income, net	603,425	-	603,425
Publications and other	265,590	-	265,590
Total support and revenue	60,247,171	-	60,247,171
EXPENSES			
Program Services	52,626,589	-	52,626,589
Supporting Services:			
Management and General	6,647,198	-	6,647,198
Total expenses	59,273,787	-	59,273,787
Changes in net assets	973,384	-	973,384
Net assets at beginning of year	2,180,058	-	2,180,058
NET ASSETS AT END OF YEAR	**$ 3,153,442**	**$ -**	**$ 3,153,442**

See accompanying notes to consolidated financial statements.

ASSOCIATION OF PUBLIC HEALTH LABORATORIES, INC. AND AFFILIATES

CONSOLIDATED STATEMENT OF FUNCTIONAL EXPENSES
FOR THE YEAR ENDED DECEMBER 31, 2020

	Program Services	Supporting Services Management and General	Total Expenses
Salaries	$ 10,032,553	$ 3,912,222	$ 13,944,775
Payroll taxes and employee benefits	3,781,325	1,538,740	5,320,065
Total salaries and benefits	13,813,878	5,450,962	19,264,840
Non-U.S. salaries and benefits	1,975,660	-	1,975,660
Subgrants and fellowships	4,259,755	-	4,259,755
Computers and equipment	1,011,925	73,486	1,085,411
Travel	894,403	4,049	898,452
Professional services	25,920,457	557,196	26,477,653
Conference and meetings	59,151	-	59,151
Office rent	39,467	1,001,469	1,040,936
Printing and copying	56,537	178,177	234,714
Office supplies	880,138	49,618	929,756
Depreciation and amortization	-	263,114	263,114
Postage and related costs	121,936	5,584	127,520
Telephone	3,812	125,793	129,605
Dues and subscriptions	101,868	30,746	132,614
Laboratory supplies and equipment	3,405,767	-	3,405,767
Insurance	130,830	71,047	201,877
Seminar fees	82,619	11,045	93,664
Other expenses	943,963	236,696	1,180,659
TOTAL	**$ 53,702,166**	**$ 8,058,982**	**$ 61,761,148**

See accompanying notes to consolidated financial statements.

ASSOCIATION OF PUBLIC HEALTH LABORATORIES, INC. AND AFFILIATES

CONSOLIDATED STATEMENT OF FUNCTIONAL EXPENSES
FOR THE YEAR ENDED DECEMBER 31, 2019

	Program Services	Supporting Services Management and General	Total Expenses
Salaries	$ 10,503,633	$ 2,813,621	$ 13,317,254
Payroll taxes and employee benefits	4,138,171	1,196,342	5,334,513
Total salaries and benefits	14,641,804	4,009,963	18,651,767
Non-U.S. salaries and benefits	1,662,758	-	1,662,758
Subgrants and fellowships	2,434,156	-	2,434,156
Computers and equipment	762,209	75,106	837,315
Travel	5,542,123	32,451	5,574,574
Professional services	19,903,992	483,276	20,387,268
Conference and meetings	1,015,231	965	1,016,196
Office rent	63,689	1,016,807	1,080,496
Printing and copying	184,152	185,183	369,335
Office supplies	1,240,481	85,606	1,326,087
Depreciation and amortization	-	289,974	289,974
Postage and related costs	296,806	4,540	301,346
Telephone	14,908	128,035	142,943
Dues and subscriptions	52,067	19,362	71,429
Laboratory supplies and equipment	3,868,923	-	3,868,923
Insurance	196,595	143,148	339,743
Seminar fees	268,230	13,349	281,579
Other expenses	478,465	159,433	637,898
TOTAL	**$ 52,626,589**	**$ 6,647,198**	**$ 59,273,787**

ASSOCIATION OF PUBLIC HEALTH LABORATORIES, INC. AND AFFILIATES

CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019

	2020	2019
CASH FLOWS FROM OPERATING ACTIVITIES		
Changes in net assets	$ 2,488,966	$ 973,384
Adjustments to reconcile changes in net assets to net cash provided by operating activities:		
Depreciation and amortization	263,114	289,974
Unrealized gains on investments	(404,843)	(512,917)
Realized gains on sales of investments	(54,143)	(4,685)
Change in allowance for doubtful accounts	(13,143)	14,565
Decrease (increase) in:		
Accounts receivable	336,769	(262,919)
Grants and contracts receivable	(1,899,673)	(487,537)
Prepaid expenses and other assets	(1,525,716)	(101,273)
Increase (decrease) in:		
Accounts payable	1,930,869	(274,711)
Accrued expenses	(480,383)	1,244,957
Deferred revenue and refundable advances	1,326,894	71,189
Deferred rent and improvement allowance	(119,369)	(93,028)
Net cash provided by operating activities	1,849,342	856,999
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchases of investments	(602,362)	(124,335)
Proceeds from sales of investments	533,760	38,997
Net cash used by investing activities	(68,602)	(85,338)
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from line of credit	-	390,984
Payments on line of credit	-	(1,050,517)
Net cash used by financing activities	-	(659,533)
Net increase in cash and cash equivalents	1,780,740	112,128
Cash and cash equivalents at beginning of year	13,288	(98,840)
CASH AND CASH EQUIVALENTS AT END OF YEAR	**$ 1,794,028**	**$ 13,288**
SUPPLEMENTAL INFORMATION:		
Interest Paid	**$ -**	**$ 43,690**

See accompanying notes to consolidated financial statements.

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GENERAL INFORMATION

Organizations -

The Association of Public Health Laboratories, Inc. (APHL) is a 501(c)(3) non-profit organization representing public health laboratories in states, territories, counties and cities throughout the United States. Its mission is to shape national and global health outcomes by promoting the value and contributions of public health laboratory system and practice.

APHL furthers its exempt purpose abroad through various subsidiaries (referred to as "Affiliates") and branch offices. Following is a summary of APHL's presence in overseas countries:

- Ghana: subsidiary organization named the Association of Public Health Laboratories Ghana (APHL Ghana).
- Tanzania: subsidiary organization named The Association of Public Health Laboratories (APHL).
- Zimbabwe: subsidiary organization named the Association of Public Health Laboratories Trust (the Trust). During November 2019, the subsidiary was closed.
- Kenya: subsidiary organization named Association of Public Health Laboratories (Kenya).
- Mozambique: branch office under the name Association of Public Health, Inc. (APHL Mozambique).
- Uganda: branch office under the name The Association of Public Health Laboratories, Inc. (APHL Uganda). The branch did not have any financial activity during the years ended December 31, 2020 and 2019.
- Zambia: branch office named The Association of Public Health Laboratories Inc. (APHL Zambia).

Consolidation -

The consolidated financial statements include the accounts of the Association of Public Health Laboratories, Inc. and Affiliates, collectively referred to as "the Association". All intercompany transactions and balances have been eliminated in consolidation.

Basis of presentation -

The accompanying consolidated financial statements are presented on the accrual basis of accounting, and in accordance with Subtopic Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 958-810, *Consolidation*, and FASB Accounting Standards Update (ASU) 2016-14, *Presentation of Financial Statements of Not-for-Profit Entities*. As such, net assets are reported within two net asset classifications: without donor restrictions and with donor restrictions; descriptions of the two net asset categories are as follows:

- **Net Assets Without Donor Restrictions** - Net assets available for use in general operations and not subject to donor restrictions are recorded as "net assets without donor restrictions". Assets restricted solely through the actions of the Board are referred to as Board designated and are also reported as net assets without donor restrictions.

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GENERAL INFORMATION (Continued)

Basis of presentation (continued) -

- **Net Assets With Donor Restrictions -** Contributions restricted by donors are reported as increases in net assets without donor restrictions if the restrictions expire (that is, when a stipulated time restriction ends or purpose restriction is accomplished) in the reporting period in which the revenue is recognized. All other donor-restricted contributions are reported as increases in "net assets with donor restrictions", depending on the nature of the restrictions. When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the Consolidated Statements of Activities and Changes in Net Assets as net assets released from donor restrictions. Gifts of long-lived assets and gifts of cash restricted for the acquisition of long-lived assets are recognized as revenue without donor restrictions when the assets are placed in service.

Cash and cash equivalents -

The Association considers all cash and other highly liquid investments with initial maturities of three months or less to be cash equivalents, excluding money market funds held by investment managers in the amount of $19,756 and $14,950 as of December 31, 2020 and 2019, respectively.

Bank deposit accounts are insured by the Federal Deposit Insurance Corporation (FDIC) up to a limit of $250,000. At times during the year, the Association maintains cash balances in excess of the FDIC insurance limits. Management believes the risk in these situations to be minimal.

As of December 31, 2020 and 2019, the Association held $2,916 and $5,793, respectively, of cash and cash equivalents in foreign countries. The majority of such funds are not insured.

Investments -

Investments are recorded at their readily determinable fair value. Realized and unrealized gains and losses are included in investment income, net of external fees in the accompanying Consolidated Statements of Activities and Changes in Net Assets.

Accounts receivable -

Accounts receivable are recorded at net realizable value, which approximates fair value. Accounts receivable consists primarily of exhibit space fees, meeting and course registrations and other trade receivables.

The allowance for doubtful accounts is based on management's evaluation of the collectability of receivables. Management determines the allowance for doubtful accounts by regularly evaluating individual customer's receivables and considering a customer's financial condition, credit history, and current economic conditions. Accounts receivable are written off when deemed uncollectable. Recoveries of receivables previously written off are recorded when received. A receivable is considered past due when any portion of the receivable balance is outstanding for more than 90 days; however, the Association does not charge interest on past due balances.

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GENERAL INFORMATION (Continued)

Grants and contracts receivable -

Grants and contracts receivable includes amounts due under Federal and non-Federal grants and other contracts, and are comprised of qualifying direct and indirect costs due the Association that are required to be reimbursed in accordance with donor agreements. Funds received in advance of incurring qualifying expenses are recorded as refundable advances.

Fixed assets -

Fixed assets acquisitions in excess of $5,000 are capitalized and stated at cost. Equipment purchased with Federal funds is expensed to the Association's programs if title transfers to the recipient organizations, or if recipients maintain physical control of the assets during the funding period.

Fixed assets are depreciated on a straight-line basis over the estimated useful lives of the related assets, generally three to ten years. Website redesign is being amortized over three years, in accordance with Accounting Standards Update (ASU) 2019-06, *Intangibles-Goodwill and Other* (Topic 350). Leasehold improvements (including tenant improvement allowances) are amortized over the remaining life of the lease. The cost of maintenance and repairs is recorded as expenses are incurred. Depreciation and amortization expense during the years ended December 31, 2020 and 2019 totaled $263,114 and $289,974, respectively.

Income taxes -

APHL is exempt from Federal income taxes under Section 501(c)(3) of the Internal Revenue Code. Accordingly, no provision for income taxes has been made in the accompanying consolidated financial statements. APHL is not a private foundation. The Affiliates and branch offices noted in the "Organizations" section above are registered (in each respective country) as tax-exempt organizations.

Uncertain tax positions -

For the years ended December 31, 2020 and 2019, the Association has documented its consideration of FASB ASC 740-10, *Income Taxes*, that provides guidance for reporting uncertainty in income taxes and has determined that no material uncertain tax positions qualify for either recognition or disclosure in the consolidated financial statements.

Sources of revenue -

Grants and Contracts - Through cooperative agreements with Centers for Disease Control and Prevention (CDC) and other Federal agencies, including the Health Resources and Services Administration (HRSA) and the Food and Drug Administration (FDA), APHL: (1) provides training to public health laboratories; (2) collects information from public health laboratories for the purpose of characterizing the PHL system, and disseminates information to them; (3) works with appropriate Federal agencies and member laboratories to facilitate the transfer and exchange of information relevant to public health laboratories; (4) supports the implementation of the President's Emergency Plan for AIDS Relief (PEPFAR) as appropriate and funded; (5) advocates, shapes the development and provides technical/management assistance to foster in-country national public health laboratory systems held to international standards through the Strengthening Public Health Laboratories Internationally (SPHLI) agreement.

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GENERAL INFORMATION (Continued)

Sources of revenue (continued) -

Grants and Contracts (continued) - Is a national newborn screening resource center designed to provide data, technical assistance, and training to newborn screening programs and assist states with quality improvement initiatives, with the goal of improving outcomes for newborns; (7) assists human and animal food regulatory testing laboratories in developing and maintaining quality systems in order to enhance mutual reliance between FDA and the states; and support FDA's goal to develop a fully integrated food safety system by supporting state governmental food laboratory accreditation, training and regulatory surveillance activities; and (8) to support facilitation of hurricane recovery efforts in Puerto Rico, US Virgin Islands and Houston that focuses on human resource capacity, procurement of equipment, travel logistics, and technical assistance through our Crisis Response agreement.

Membership - Membership services include the costs associated with providing key benefits to members. Such benefits include the quarterly magazine, weekly electronic newsletter, and information on Federal and state legislative activities as well as advocacy efforts.

Conferences and Exhibits - Conferences are developed to encourage laboratory scientists to discuss and debate critical and urgent laboratory issues. These conferences promote information exchange and provide recommendations that have a practical value in the diagnosis and control of disease. APHL also develops and delivers training programs designed to help laboratorians improve their technical and leadership skills.

AIMS Platform - APHL has signed revenue contracts with numerous customers, in which APHL provides services related to the transport, validation, routing and receipt of electronic health and laboratory data using APHL Informatics Messaging Services (AIMS) platform developed by APHL.

Revenue recognition -

The majority of the Association's revenue is received through awards from agencies of the United States Government and other entities. Contributions and grants are recognized in the appropriate category of net assets in the period received. The Association performs an analysis of the individual award to determine if the revenue streams follow the contribution rules or if they should be recorded as an exchange transaction depending upon whether the transactions are deemed reciprocal or nonreciprocal.

For awards qualifying under the contribution rules, revenue is recognized upon notification of the award and satisfaction of all conditions, if applicable. Conditional promises to give are not recognized until the conditions on which they depend are substantially met. Awards qualifying as contributions that are unconditional that have donor restrictions are recognized as "without donor restrictions" only to the extent of actual expenses incurred in compliance with the donor imposed restrictions and satisfaction of time restrictions; such funds in excess of expenses incurred are shown as net assets with donor restrictions in the accompanying consolidated financial statements.

Awards qualifying as conditional contributions contain a right of return or right of release from obligation provision and a defined barrier (or barriers), and the entity has limited discretion over how funds transferred should be spent. Accordingly, revenue is recognized when the condition or conditions are satisfied (when the related barrier has been overcome; generally, when qualifying expenditures are incurred); these transactions are nonreciprocal and classified as conditional, and are recognized as contributions when the revenue becomes unconditional.

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GENERAL INFORMATION (Continued)

Revenue recognition (continued) -

In addition to sources of revenue deemed conditional (as described above), the Association considers all awards from agencies of the United States Government to be conditional assistance, and accordingly have been recognized in the accompanying consolidated financial statements as revenue (without donor restrictions) at such time when the conditions have been met.

Funds received (under conditional assistance awards) in advance of the incurrence of qualifying expenditures are recorded as refundable advances; total refundable advances recognized in the accompanying consolidated financial statements under conditional awards as of December 31, 2020 and 2019 aggregated $900,751 and $203,272, and are included in "deferred revenue and refundable advances" in the accompanying Consolidated Statements of Financial Position.

Corporate membership dues includes general member benefits that are a series of distinct obligations. The revenue is recognized ratably over the membership period. There are several benefits received that are individual distinct obligations such as booths at the Annual Meeting, registrations to the annual meeting, mailing list rentals and registrations to the Corporate Leadership Council Meeting. These individual distinct benefits are bifurcated amongst the different benefits received and recognized as revenue when the performance obligations are met. Transaction price is determined based on cost and/or sales price.

The Association recognizes conference and meeting revenue when the performance obligation is met which is when the related event has occurred. Publications and other income (including advertising and mailing list revenues) is recognized as revenue when the performance obligations are met which is when issued and/or billed.

The transaction price for membership dues, conference and meeting revenue as well as publications and other revenue is determined based on cost and/or sales price. Any amounts received in advance are recognized as deferred revenue in the Consolidated Statements of Financial Position. Included in deferred revenue as of December 31, 2020 and 2019 are membership dues, conference and exhibits, and unearned contract revenues.

Foreign currency translation -

The United States Dollar (USD) is the functional currency for the Association's operations. Transactions in currencies other than the USD are translated into USD at the rate of exchange in effect during the month of the transaction. Current assets and liabilities denominated in currencies other than the USD are translated into USD at the exchange rate in effect at the date of the Consolidated Statements of Financial Position.

Use of estimates -

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accordingly, actual results could differ from those estimates.

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GENERAL INFORMATION (Continued)

Functional expenses -

The costs of providing the various programs and other activities have been summarized on a functional basis in the Consolidated Statements of Activities and Changes in Net Assets. “Program Services” costs are incurred for the sole benefit of the program and are charged directly based on benefit received. “Management and General” costs are expenses that have been incurred for the joint objectives and are allocated to the programs through application of a pre-approved rate.

Investment risks and uncertainties -

The Association invests in various investment securities. Investment securities are exposed to various risks such as interest rates, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the accompanying consolidated financial statements.

Fair value measurement -

The Association adopted the provisions of FASB ASC 820, *Fair Value Measurement*. FASB ASC 820 defines fair value, establishes a framework for measuring fair value, establishes a fair value hierarchy based on the quality of inputs (assumptions that market participants would use in pricing assets and liabilities, including assumptions about risk) used to measure fair value, and enhances disclosure requirements for fair value measurements. The Association accounts for a significant portion of its financial instruments at fair value or considers fair value in their measurement.

Economic uncertainties -

On March 11, 2020, the World Health Organization declared the Coronavirus disease (COVID-19) a global pandemic. As a result of the spread of COVID-19, economic uncertainties have arisen which may negatively impact the Association's operations. The overall potential impact is unknown at this time.

New accounting pronouncement (not yet adopted) -

ASU 2019-01, *Leases* (Topic 842), changes the accounting treatment for operating leases by recognizing a lease asset and lease liability at the present value of the lease payments in the Consolidated Statement of Financial Position and disclosing key information about leasing arrangements. During 2020, the FASB issued ASU 2020-05 and delayed the implementation date by one year. The ASU is effective for non public entities beginning after December 15, 2021. Early adoption is still permitted. The ASU can be applied at the beginning of the earliest period presented using a modified retrospective approach or applied at the beginning of the period of adoption recognizing a cumulative-effect adjustment.

The Association plans to adopt the new ASU at the required implementation date and management is currently in the process of evaluating the adoption method and the impact of the new standard on its accompanying consolidated financial statements.

2. INVESTMENTS

Investments consisted of the following as of December 31, 2020 and 2019:

	2020		2019	
	Cost	Fair Value	Cost	Fair Value
Money market funds	$ 19,756	$ 19,756	$ 14,950	$ 14,950
Exchange-traded funds - Fixed income	1,145,608	1,266,956	1,157,656	1,229,275
Exchange-traded funds - Equity	1,348,235	2,495,196	1,178,225	1,974,348
Mutual funds - Fixed income	857,206	849,231	865,990	853,739
Mutual funds - Cash equivalents	170,029	170,029	201,268	201,268
TOTAL INVESTMENTS	**$ 3,540,834**	**$ 4,801,168**	**$ 3,418,089**	**$ 4,273,580**

Included in investment income, net are the following during the years ended December 31, 2020 and 2019:

	2020	2019
Interest and dividends	$ 110,253	$ 124,109
Unrealized gain on investments	404,843	512,917
Realized gain on sales of investments	54,143	4,685
Investment management fees	(41,176)	(38,286)
TOTAL INVESTMENT INCOME, NET	**$ 528,063**	**$ 603,425**

3. LINE OF CREDIT

In August 2013, the Association obtained a variable rate revolving line of credit with a financial institution for the purpose of funding office improvements, which renews automatically on an annual basis. The line is secured by the Association's investments held in accounts at the same financial institution. The maximum available balance as of December 31, 2020 and 2019 was approximately $1,500,000 and $3,000,000, respectively. The maximum available balance is based on the value of the collateral as of the close of the previous business day, less outstanding loan balances and accrued interest and fees. As of December 31, 2020 and 2019, there were no outstanding borrowings. The interest rate on borrowings as of December 31, 2020 and 2019 was 2.35% and 4.00%, respectively.

4. NET ASSETS WITH DONOR RESTRICTIONS

Net assets with donor restrictions consist of the following at December 31, 2020 and 2019:

	2020	2019
Newborn Screening Program	**$ 40,000**	**$ -**

The following net assets with donor restrictions were released from donor restrictions by incurring expenses which satisfied the restricted purposes specified by the donors:

	2020	2019
COVID-19 Public Health Response	**$ 200,000**	**$ -**

5. AVAILABILITY OF FINANCIAL ASSETS (LIQUIDITY)

Financial assets available to meet cash needs for general expenditure within one year of the date of the Consolidated Statements of Financial Position were comprised of the following as of December 31, 2020 and 2019:

	2020	2019
Cash and cash equivalents	$ 1,794,028	$ 13,288
Investments	4,801,168	4,273,580
Accounts receivable	75,206	398,832
Grants and contracts receivable	6,451,042	4,551,369
Subtotal financial assets available	13,121,444	9,237,069
Less: Donor restricted funds	(40,000)	-
FINANCIAL ASSETS AVAILABLE TO MEET CASH NEEDS FOR GENERAL EXPENDITURES WITHIN ONE YEAR	**$ 13,081,444**	**$ 9,237,069**

The Association maintains financial assets of $13,081,444 and $9,237,069 as of December 31, 2020 and 2019, respectively, to support its general operations during the next calendar year. These assets include cash, investments, and receivables. The Association does not maintain any Board designated or donor restricted cash (or endowments).

The Association’s goal is to maintain financial assets to meet six months of normal operating expenses. Also, explained in more detail in Note 3 of the consolidated financial statements, the Association has a committed line of credit in the amount of $1,500,000 which is secured against its investments; the line allows the Association to access funds without liquidating investments should market conditions indicate that is a more favorable approach.

6. LEASE COMMITMENTS

The Association leases office space in Silver Spring, Maryland under an agreement set to expire on November 30, 2023. The lease includes an annual rent escalation of 2.5% per year, and the Association is required to pay its proportionate share of real estate taxes and building operating costs. Accounting principles generally accepted in the United States of America require that the total rent commitment should be recognized on a straight-line basis over the term of the lease. Accordingly, the difference between the actual monthly payments and the rent expense being recognized for financial statement purposes is recorded as a deferred rent liability in the accompanying Consolidated Statements of Financial Position. As of December 31, 2020 and 2019, the difference between the actual monthly payments and the straight-line basis aggregated $322,880 and $380,211, respectively.

In addition, the Association's lease includes an improvement allowance of $595,740 (which has been fully utilized). Accounting principles generally accepted in the United States of America require that leasehold improvement allowances be recorded as assets (leasehold improvements) with a corresponding liability (deferred improvement allowance). As of December 31, 2020 and 2019, the total deferred improvement allowance recorded in the accompanying Consolidated Statements of Financial Position aggregated $180,942 and $242,980, respectively.

The Association also maintains office space in various countries under short-term operating leases.

6. LEASE COMMITMENTS (Continued)

Following is a schedule of the future minimum lease payments under all leases (worldwide) as of December 31, 2020 and 2019:

Year Ending December 31,	2020	2019
2020	$ -	$ 1,091,302
2021	1,134,038	1,106,715
2022	1,134,320	1,134,320
2023	1,063,572	1,063,572
	$ 3,331,930	**$ 4,395,909**

Office rent expense during the years ended December 31, 2020 and 2019 totaled $1,040,936 and $1,080,495, respectively. As of December 31, 2020 and 2019, the balance of the deferred rent and improvement allowance liability aggregated $503,822 and $623,191, respectively.

7. RETIREMENT PLAN

The Association provides retirement benefits to its employees through a defined contribution plan covering employees over eighteen years of age with three months of eligible experience. The Association contributes 10% percent of eligible employee compensation. Contributions to the Plan during the years ended December 31, 2020 and 2019 totaled $1,327,481 and $1,233,831, respectively, and are included in payroll taxes and employee benefits in the accompanying Consolidated Statements of Functional Expenses.

8. CONCENTRATION OF RECEIVABLES AND REVENUE

Approximately 88% and 96% of the Association's revenue for the years ended December 31, 2020 and 2019, respectively, were derived from funding agreements with agencies of the United States Government. Approximately 78% and 96% of the Association's receivables as of the years ended December 31, 2020 and 2019, respectively were due from agencies of the United States Government. The Association has no reason to believe that relationships with these agencies will be discontinued in the foreseeable future. However, any interruption of these relationships (i.e., the failure to renew grant agreements or withholding of funds) would adversely affect the Association's ability to finance ongoing operations.

9. CONTINGENCY

The Association receives awards from various agencies of the United States Government. Such awards are subject to audit under the provisions of *Title 2 U.S. Code of Federal Regulations (CFR) Part 200 Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance)*. The ultimate determination of amounts received under the United States Government awards is based upon the allowance of costs reported to and accepted by the United States Government as a result of the audits. Audits in accordance with the applicable provisions have been completed for all required fiscal years through 2020. Until such audits have been accepted by the United States Government, there exists a contingency to refund any amount received in excess of allowable costs. Management is of the opinion that no material liability will result from such audits.

10. COMMITMENTS

The Association is committed under agreements for conference space through the year 2022. The agreements indicate that the Association is liable for liquidated damages in the event of cancellation. As of December 31, 2020 and 2019, the Association's commitment for liquidated damages, assuming no rooms are resold, is estimated to be approximately $400,000 and $780,000, respectively.

The Association has an employment agreement with its Chief Executive Officer. This agreement requires that the Association pay the Chief Executive Officer an amount equal to nine months salary if the Association terminates the Chief Executive Officer without cause.

11. FAIR VALUE MEASUREMENT

In accordance with FASB ASC 820, *Fair Value Measurement*, the Association has categorized its financial instruments, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure the financial instruments fall within different levels of hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

Investments recorded in the accompanying Consolidated Statements of Financial Position are categorized based on the inputs to valuation techniques as follows:

Level 1. These are investments where values are based on unadjusted quoted prices for identical assets in an active market the Association has the ability to access.

Level 2. These are investments where values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuation techniques that utilize inputs that are observable either directly or indirectly for substantially the full-term of the investments.

Level 3. These are investments where inputs to the valuation methodology are unobservable and significant to the fair value measurement.

Following is a description of the valuation methodology used for investments measured at fair value. There have been no changes in the methodologies used as of December 31, 2020 and 2019.

- *Money market funds* - Valued at the daily closing price as reported by the fund. The money market fund is an open-end mutual fund that is registered with the Securities and Exchange Commission (SEC). This fund is required to publish its daily net asset value (NAV) and to transact at that price. The money market fund is deemed to be actively traded.

- *Exchange-traded funds (fixed income and equity)* - Valued at the closing price reported on the active market in which the individual securities are traded.

- *Mutual funds (fixed income)* - Valued at the daily closing price as reported by the fund. Mutual funds held by the Association are open-end funds that are registered with the SEC. These funds are required to publish their NAV and to transact at that price. The mutual funds held by the Association are deemed to be actively traded.

11. FAIR VALUE MEASUREMENT (Continued)

The table below summarizes, by level within the fair value hierarchy, the Association's investments as of December 31, 2020:

	Level 1	Level 2	Level 3	Total
Asset Class:				
Money market funds	$ 19,756	$ -	$ -	$ 19,756
Exchange-traded funds - Fixed income	1,266,956	-	-	1,266,956
Exchange-traded funds - Equity	2,495,196	-	-	2,495,196
Mutual funds - Fixed income	849,231	-	-	849,231
Mutual funds - Cash equivalents	170,029	-	-	170,029
TOTAL	**$ 4,801,168**	**$ -**	**$ -**	**$ 4,801,168**

The table below summarizes, by level within the fair value hierarchy, the Association's investments as of December 31, 2019:

	Level 1	Level 2	Level 3	Total
Asset Class:				
Money market funds	$ 14,950	$ -	$ -	$ 14,950
Exchange-traded funds - Fixed income	1,229,275	-	-	1,229,275
Exchange-traded funds - Equity	1,974,348	-	-	1,974,348
Mutual funds - Fixed income	853,739	-	-	853,739
Mutual funds - Cash equivalents	201,268	-	-	201,268
TOTAL	**$ 4,273,580**	**$ -**	**$ -**	**$ 4,273,580**

12. SUBSEQUENT EVENTS

In preparing these consolidated financial statements, the Association has evaluated events and transactions for potential recognition or disclosure through , the date the consolidated financial statements were issued.

SUPPLEMENTAL INFORMATION

ASSOCIATION OF PUBLIC HEALTH LABORATORIES, INC. AND AFFILIATES

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR ASSOCIATION OF PUBLIC HEALTH LABORATORIES, INC. FOR THE YEAR ENDED DECEMBER 31, 2020

Federal Granting Agency and Program Title	Internal Title	CFDA Number	Pass-Through Entity	Pass-Through Entity Identifying Number	Passed Through to Subrecipients	Expenditures
Department of Health and Human Services						
Activities to Support State, Tribal, Local and Territorial (STLT) Health Department Response to Public Health or Healthcare	APHL Lab Technical Assistance for Response to PH Crises	93.391	N/A	N/A	$ -	$ 6,064,491
Global Aids	APHL-CDC Partnership: Support Laboratory Strengthening Activities in Resource-Limited Countries under PEPFAR	93.067	N/A	N/A	-	1,099,324
Global Aids	Scaling High Quality Laboratory Services for HIV Diagnosis, Care, Treatments and Monitoring in Mozambique under PEPFAR	93.067	N/A	N/A	350,000	1,223,743
Global Aids	Strengthen the Quality, Accessibility, and Sustainability of the National Health Laboratories, Service of the United Republic Tanzania under PEPFAR	93.067	Tanzania Health Promotion Support	CDC-RFA-GH18-1812 & 2GGH002125	-	215,841
Global Aids	Laboratory Innovation for Excellence (LIFE)	93.067	Centre for Infectious Disease Research in Zambia (CIDRZ)	M100 F1 NU2GGH0021 22-01-00, M100FC NU2GGH0021 22-02-02 & M100F1NU2G GH002122-03	-	1,248,154
Global Aids	Regional Strengthening of HIV-Focused Population-based National Survey and Size Estimations (RESPONSE)	93.067	University of Maryland, Baltimore	F212422	-	74,400
Subtotal 93.067					**350,000**	**3,861,462**

ASSOCIATION OF PUBLIC HEALTH LABORATORIES, INC. AND AFFILIATES

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR ASSOCIATION OF PUBLIC HEALTH LABORATORIES, INC. FOR THE YEAR ENDED DECEMBER 31, 2020

Federal Granting Agency and Program Title	Internal Title	CFDA Number	Pass-Through Entity	Pass-Through Entity Identifying Number	Passed Through to Subrecipients	Expenditures
Department of Health and Human Services (Continued)						
Maternal and Child Health Federal Consolidated Programs	Health Resources and Services Administration Heritable Disorders	93.110	N/A	N/A	$ 326,817	$ 1,686,244
Maternal and Child Health Federal Consolidated Programs	Improving Timeliness of Newborn Screening Diagnosis	93.110	N/A	N/A	1,131,891	2,908,351
Maternal and Child Health Federal Consolidated Programs	Follow up in Newborn Screening	93.110	N/A	N/A	-	130
Maternal and Child Health Federal Consolidated Programs	Severe Combined Immunodeficiency SCID Screening and Education	93.110	Immune Deficiency Foundation (IDF)	APHL 80118.2 & APHL 80118.3	-	242,891
Maternal and Child Health Federal Consolidated Programs	Maternal and Child Health Telehealth Capacity for Public Health Systems	93.110	Association of Maternal & Child Health Programs (AMCHP)	H7DMC37565 0100	-	16,341
Subtotal 93.110					**1,458,708**	**4,853,957**
Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security	APHL-CDC Partnership: Strengthening Public Health Laboratories	93.318	N/A	N/A	90,000	4,366,056
Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security	Expanding Efforts and Strategies to Protect and Improve Public Health in Kenya	93.318	N/A	N/A	-	179,490
Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security	Global Health Security Partnerships: Expanding and Improving Public Health Laboratory Strategies and Systems	93.318	N/A	N/A	-	259,133
Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security	APHL-CDC Partnership: Support Laboratory Strengthening Activities in Resource-Limited Countries under PEPFAR	93.318	N/A	N/A	-	(7,609)
Subtotal 93.318					**90,000**	**4,797,070**

ASSOCIATION OF PUBLIC HEALTH LABORATORIES, INC. AND AFFILIATES

**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR
ASSOCIATION OF PUBLIC HEALTH LABORATORIES, INC.
FOR THE YEAR ENDED DECEMBER 31, 2020**

Federal Granting Agency and Program Title	Internal Title	CFDA Number	Pass-Through Entity	Pass-Through Entity Identifying Number	Passed Through to Subrecipients	Expenditures
Department of Health and Human Services (Continued)						
CSELS Partnership Strengthening Public Health Laboratories	APHL-CDC Partnership: Strengthening Public Health Laboratories	93.322	N/A	N/A	$ 597,882	$ 24,279,522
CSELS Partnership Strengthening Public Health Laboratories	Enhancing Public Health Laboratory Capabilities and Increasing Capacity	93.322	N/A	N/A	15,706	11,202,951
Subtotal 93.322					**613,588**	**35,482,473**
Laboratory Leadership, Workforce Training and Management Development, Improving Public Health Laboratory Infrastructure	APHL-CDC Partnership: Support Laboratory Strengthening Activities in Resource-Limited Countries under PEPFAR (Ebola Funds)	93.065	N/A	N/A	-	(4,280)
Total Department of Health and Human Services					**2,512,296**	**55,055,173**
Food and Drug Administration						
Food and Drug Administration Research	Maintain Enhance ISO/IEC 17025 Accred and WGS Food Test Labs	93.103	N/A	N/A	-	104,017
Food and Drug Administration Research	Leveraging Technical Resources for ISO/IEC 17025 Laboratory Accreditation, Genome Trakr and Elexnet	93.103	N/A	N/A	-	24,459
Food and Drug Administration Research	National Laboratory Curriculum Framework Development	93.103	N/A	N/A	-	545,401
Food and Drug Administration Research	Building an Integrated Laboratory System to Advance the Safety of Human and Animal Food	93.103	N/A	N/A	-	161,164
Food and Drug Administration Research	FDA's National Curriculum Standard Development and Training Delivery and Development (U18)	93.103	N/A	N/A	-	207,181
Total CFDA 93.103 and Food and Drug Administration					**-**	**1,042,222**
TOTAL EXPENDITURES OF FEDERAL AWARDS					**$ 2,512,296**	**$ 56,097,395**

ASSOCIATION OF PUBLIC HEALTH LABORATORIES, INC. AND AFFILIATES

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR
ASSOCIATION OF PUBLIC HEALTH LABORATORIES, INC.
FOR THE YEAR ENDED DECEMBER 31, 2020

Note 1. Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards (the Schedule) includes the Federal award activity of the Association under programs of the United States Government during the year ended December 31, 2020. The information in this Schedule is presented in accordance with the requirements of *Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance).* Because the Schedule presents only a selected portion of the operations of the Association, it is not intended to and does not present the financial position, changes in net assets or cash flows of the Association.

Note 2. Summary of Significant Accounting Policies

Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Negative amounts shown on the Schedule represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years. The Association has elected not to use the 10-percent de minimis indirect cost rate as allowed under Uniform Guidance.

Note 3. Reconciliation of Financial Statements to Schedule of Expenditures of Federal Awards

Grants and contracts per the Consolidated Statement of Activities and Change in Net Assets	$ 61,776,063
Less: Contracts and other income not subject to Uniform Guidance	5,678,668
TOTAL EXPENDITURES OF FEDERAL AWARDS	**$ 56,097,395**

ASSOCIATION OF PUBLIC HEALTH LABORATORIES, INC. AND AFFILIATES

SCHEDULE OF FINDINGS AND QUESTIONED COSTS FOR ASSOCIATION OF PUBLIC HEALTH LABORATORIES, INC. FOR THE YEAR ENDED DECEMBER 31, 2020

Section I - Summary of Auditor's Results

Financial Statements

1). Type of auditor's report issued on whether the financial statements audited were prepared in accordance with GAAP on the accrual basis of accounting: **Unmodified**

2). Internal control over financial reporting:

- Material weakness(es) identified? ☐ **Yes** ☒ **No**
- Significant deficiency(ies) identified? ☐ **Yes** ☒ **None Reported**
- Other matter of noncompliance noted? ☐ **Yes** ☒ **No**

3). Noncompliance material to financial statements noted? ☐ **Yes** ☒ **No**

Federal Awards

4). Internal control over major federal programs:

- Material weakness(es) identified? ☐ **Yes** ☒ **No**
- Significant deficiency(ies) identified? ☐ **Yes** ☒ **None Reported**

5). Type of auditor's report issued on compliance for major federal programs: **Unmodified**

6). Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)? ☐ **Yes** ☒ **No**

7). Identification of major federal programs:

Federal Program Title	CFDA Number	Expenditures
CSELS Partnership: Strengthening Public Health Laboratories	93.322	$ 35,482,473

8). Dollar threshold used to distinguish between Type A and Type B programs: **$1,682,922**

9). Auditee qualified as a low-risk auditee? ☒ **Yes** ☐ **No**

ASSOCIATION OF PUBLIC HEALTH LABORATORIES, INC. AND AFFILIATES

**SCHEDULE OF FINDINGS AND QUESTIONED COSTS FOR
ASSOCIATION OF PUBLIC HEALTH LABORATORIES, INC.
FOR THE YEAR ENDED DECEMBER 31, 2020**

Section II - Financial Statement Findings

There were no reportable findings.

Section III - Federal Award Findings and Questioned Costs (2 CFR 200.516(a))

There were no reportable findings.

REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS

Independent Auditor's Report

To the Board of Directors
Association of Public Health Laboratories, Inc. and Affiliates
Silver Spring, Maryland

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of the Association of Public Health Laboratories, Inc. and Affiliates (collectively, the Association) as of and for the year ended December 31, 2020, and the related notes to the consolidated financial statements, which collectively comprise the basic consolidated financial statements of the Association of Public Health Laboratories, Inc. (APHL), and have issued our report thereon dated .

Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered APHL's internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances, for the purpose of expressing our opinions on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of APHL's internal control. Accordingly, we do not express an opinion on the effectiveness of APHL's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of APHL's consolidated financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit, we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Association's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM AND REPORT ON INTERNAL CONTROL OVER COMPLIANCE REQUIRED BY TITLE 2 U.S. CODE OF FEDERAL REGULATIONS (CFR) PART 200, UNIFORM ADMINISTRATIVE REQUIREMENTS, COST PRINCIPLES, AND AUDIT REQUIREMENTS FOR FEDERAL AWARDS (UNIFORM GUIDANCE)

Independent Auditor's Report

To the Board of Directors
Association of Public Health Laboratories, Inc. and Affiliates
Silver Spring, Maryland

Report on Compliance for Each Major Federal Program

We have audited the Association of Public Health Laboratories, Inc.'s compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on each of APHL's major Federal programs for the year ended December 31, 2020. APHL's major Federal programs are identified in the summary of auditor’s results section of the accompanying Schedule of Findings and Questioned Costs.

Management’s Responsibility

Management is responsible for compliance with the Federal statutes, regulations, and the terms and conditions of its Federal awards applicable to its Federal programs.

Auditor’s Responsibility

Our responsibility is to express an opinion on compliance for each of APHL's major Federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of *Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles and Audit Requirements for Federal Awards (Uniform Guidance).* Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major Federal program occurred. An audit includes examining, on a test basis, evidence about APHL's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major Federal program. However, our audit does not provide a legal determination of APHL's compliance.

Opinion on Each Major Federal Program

In our opinion, APHL complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major Federal programs for the year ended December 31, 2020.

Report on Internal Control Over Compliance

Management of APHL is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered APHL's internal control over compliance with the types of requirements that could have a direct and material effect on each major Federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major Federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of APHL's internal control over compliance.

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a Federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a Federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a Federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

2020 Total Corporate Support

Total: $698,280.50



Companies Providing Support to APHL
January–December 2020

Membership Dues

Abbott
Applied Maths/Biomerieux
Arcbio
Baebies
Bio-Rad Laboratories
Bruker
Cepheid
Chembio Diagnostic Systems
ChromaCode
Clear Labs
CLSI
DiaSorin
EzBiome
HDR
Hologic
HOK
Horizon Lab Systems
iConnect Consulting
IDEXX
Illumina
J Michael Consulting
LIMS ABC
Luminex
MediaLab, Inc.
MetaSystems
MRIGlobal
National Jewish Health
OpenELIS
Oxford Nanopore Technologies
OZ Systems
PerkinElmer
Promega
Puritan Medical Products
QIAGEN
Quantabio
Roche Diagnostics
Ruvos
SCIEX
SpeeDx
STACS DNA
Streck
Theiagen Consulting LLC
Thermo Fisher Scientific
Waters
Worldwide Diagnostics

Conference and Meeting Support

Abbott
Applied Maths/Biomerieux
ArcBio
Astoria-Pacific
Baebies
Biogen
Bio-Rad Laboratories
Biotage
Cambridge Isotope
Cepheid
ChunLab (EzBiome)
Clear Labs
CLSI
DiaSorin
EBF Inc.
Fujirebio US
Gold Standard Diagnostics
HOK
Hologic
Horizon Lab Systems
iConnect Consulting
IDEXX
Illumina
InBios International
INTEGRA Biosciences
Integrated Software Solutions
J Michael Consulting
LIMS ABC
MRIGlobal
National Jewish Health
OpenELIS
Orchard Software
Oxford Nanopore Technologies
OZ Systems
PerkinElmer
Puritan Medical Products
QIAGEN
Quantabio
Roche Diagnostics
Ruvos
SCIEX
Sebia
SmartGene
SpeeDx
STACS DNA
Streck
Thermo Fisher Scientific
Waters
Worldwide Diagnostics

Miscellaneous Support

HDR
Hologic
Perkin Elmer
Agena Biosciences
American Biological Safety Association
LabVantage
Tubewriter